Apellis Pharmaceuticals, Inc.
APLS
$23.19
-$0.30-1.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -10.61% | -3.21% | 45.19% | 78.29% | 110.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.61% | -3.21% | 45.19% | 78.29% | 110.26% |
| Cost of Revenue | -20.19% | 15.13% | 31.41% | 19.93% | -2.87% |
| Gross Profit | -0.80% | -31.74% | 66.69% | 771.90% | 1,187.76% |
| SG&A Expenses | 2.39% | -0.12% | -14.27% | -16.25% | 15.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.57% | 6.70% | 3.38% | -1.36% | 6.37% |
| Operating Income | -13.05% | -34.21% | 69.04% | 65.51% | 75.55% |
| Income Before Tax | -11.03% | -38.69% | 58.62% | 59.39% | 69.19% |
| Income Tax Expenses | 308.77% | 100.59% | -79.90% | 154.08% | -41.24% |
| Earnings from Continuing Operations | -11.93% | -38.84% | 58.96% | 59.04% | 69.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.93% | -38.84% | 58.96% | 59.04% | 69.14% |
| EBIT | -13.05% | -34.21% | 69.04% | 65.51% | 75.55% |
| EBITDA | -13.26% | -34.45% | 69.40% | 65.73% | 75.84% |
| EPS Basic | -10.07% | -36.08% | 60.05% | 60.34% | 70.29% |
| Normalized Basic EPS | -15.15% | -35.93% | 59.72% | 60.68% | 71.87% |
| EPS Diluted | -10.07% | -36.08% | 60.05% | 60.34% | 70.29% |
| Normalized Diluted EPS | -15.15% | -35.93% | 59.72% | 60.68% | 71.87% |
| Average Basic Shares Outstanding | 1.71% | 2.03% | 2.71% | 3.28% | 3.85% |
| Average Diluted Shares Outstanding | 1.71% | 2.03% | 2.71% | 3.28% | 3.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |